KYORIN Pharmaceutical (4569) · TargetRestated
Carbon Neutrality by 2050 and a 46% Reduction in CO2 Emissions by FY2030
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2024.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
GHG emissions (Scopes 1–3): calculation, emissions-reduction target-setting and renewable energy procurementA theme 999 companies write about · 7 as a headwind · 1055 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 1063 threads.Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「We have set the achievement of carbon neutrality by 2050 as a challenge and are working to reduce CO2 emissions by considering a phased transition to renewable energy and new capital investment toward the target of reducing CO2 emissions by 46% in fiscal 2030 from fiscal 2015 levels.」
The Company continues to target carbon neutrality by 2050 and a 46% reduction in CO2 emissions in fiscal 2030 from fiscal 2015 levels, citing the transition to renewable energy and capital investment as measures. - FY2023First statedAnnual report
「We will take on the challenge of achieving carbon neutrality by 2050. Specifically, we have set a target of reducing CO2 emissions by 46% from FY2015 levels by FY2030.」
The Group set a carbon-neutrality target for 2050 and a numerical target of reducing CO2 emissions by 46% from FY2015 levels by FY2030.